Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP Inhibitor”

315 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 315 results

Large-scale testing (Phase 3)Ended earlyNCT02470585
What this trial is testing

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerOvarian Neoplasm
AbbVie 1,140
Early research (Phase 1)Looking for participantsNCT05870423
What this trial is testing

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

Who this might be right for
Neuroendocrine TumorsPeptide Receptor Radionuclide Therapy
Erasmus Medical Center 24
Testing effectiveness (Phase 2)Looking for participantsNCT06844383
What this trial is testing

Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Who this might be right for
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium 126
Not applicableLooking for participantsNCT06588322
What this trial is testing

Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy

Who this might be right for
Ovarian Cancer
Institut Claudius Regaud 130
Testing effectiveness (Phase 2)Ended earlyNCT03875313
What this trial is testing

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Who this might be right for
Solid TumorClear Cell Renal Cell CarcinomaTNBC - Triple-Negative Breast Cancer+4 more
Calithera Biosciences, Inc 33
Large-scale testing (Phase 3)Active Not RecruitingNCT01844986
What this trial is testing

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Who this might be right for
Newly DiagnosedAdvanced Ovarian CancerFIGO Stage III-IV+4 more
AstraZeneca 450
Early research (Phase 1)Active Not RecruitingNCT06545942
What this trial is testing

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorProstate Cancer+4 more
MOMA Therapeutics 220
Testing effectiveness (Phase 2)Ended earlyNCT03891576
What this trial is testing

Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Mario Negri Institute for Pharmacological Research 83
Testing effectiveness (Phase 2)Active Not RecruitingNCT06433219
What this trial is testing

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Who this might be right for
Ovarian Cancer
EMD Serono Research & Development Institute, Inc. 63
Not applicableNot Yet RecruitingNCT06242392
What this trial is testing

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Fujian Cancer Hospital 250
Testing effectiveness (Phase 2)Ended earlyNCT02576444
What this trial is testing

OLAParib COmbinations

Who this might be right for
Cancer
Joseph Paul Eder 67
Testing effectiveness (Phase 2)Study completedNCT03167619
What this trial is testing

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)

Who this might be right for
Triple Negative Breast Cancer
Duke University 45
Early research (Phase 1)Study completedNCT04335604
What this trial is testing

NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Onconic Therapeutics Inc. 62
Testing effectiveness (Phase 2)Active Not RecruitingNCT03880019
What this trial is testing

A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

Who this might be right for
Stage III Uterine Corpus Leiomyosarcoma AJCC v8Stage IV Uterine Corpus Leiomyosarcoma AJCC v8Uterine Corpus Leiomyosarcoma
National Cancer Institute (NCI) 23
Early research (Phase 1)Study completedNCT00994071
What this trial is testing

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

Who this might be right for
MedulloblastomaPontine GliomaEpendymoma+2 more
National Cancer Institute (NCI) 9
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06544460
What this trial is testing

Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients

Who this might be right for
Ovarian Cancer
Fudan University 94
Testing effectiveness (Phase 2)Study completedNCT03427814
What this trial is testing

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Who this might be right for
Advanced or Inoperable Gastric Cancer
BeiGene 136
Not applicableApproved For MarketingNCT03079687
What this trial is testing

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Who this might be right for
Ovarian Cancer
AstraZeneca
Large-scale testing (Phase 3)Study completedNCT02855944
What this trial is testing

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+1 more
pharmaand GmbH 349
Not applicableActive Not RecruitingNCT07303218
What this trial is testing

The HER Project: HRD in EGFR-mutated NSCLC

Who this might be right for
EGFRNon Small Cell Lung CancerHomologous Recombination Deficiency+1 more
IRCCS San Raffaele 100
Load More Results